Group items matching

in title, tags, annotations or url

Mental health issues are very common, and one in four people will experience a mental health problem in their lifetime. Unfortunately, many people do not seek treatment because they are embarrassed or ashamed. However, there is no need to be ashamed - mental health problems are just like any other medical condition. Treatment options include therapy, medication, and lifestyle changes. In this blog post, we will discuss the top ways medications can help in treating mental health issues. We will also dispel some of the myths about mental health medications. MENTAL HEALTH MEDICATIONS CAN REDUCE ANXIETY AND DEPRESSION Mental health medications can be very effective in treating mental illness. In fact, they can be just as effective as medications for physical health conditions. Mental health medications can help to reduce symptoms, improve functioning, and prevent relapses. They are also legal psychedelic medicine that have been shown to be helpful in treating mental illness. For example, ketamine has been shown to be effective in treating depression, anxiety, and post-traumatic stress disorder. Some people worry that taking mental health medication will make them feel like a different person. However, this is not the case. Mental health medications can help you to feel like yourself again. They can also help you to function better in your everyday life.

Colonis, a subsidiary company of the Clinigen Group has received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD). Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25%-50%. Sleep onset insomnia in children with ADHD can affect their mood, attention, behaviour and school performance. Henno Welgemoed, Director of Medical Affairs at Colonis said: "We welcome the MHRA's approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks."

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.

Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health. A CLOSER LOOK AT DIABETES Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D). Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes. Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin therapy to manage type 2 diabetes. GLP-1 RECEPTOR AGONISTS A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.

Nasal endoscopy is used to examine and diagnose conditions affecting the nose and sinuses. It involves the use of a thin, flexible tube called an endoscope to provide a detailed view of the nasal cavity.

https://viesearch.com/1yu6d/common-pancreatic-disorders-that-require-surgical

A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages. NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and Hormone Replacement Therapy (HRT) drugs. The report highlights the impact of affected medicine supply issues on community pharmacies and patients. Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be as bad as they have ever been". She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

Maintaining good personal hygiene is among the most effective defenses against gastrointestinal and infectious disorders such as the flu, and the common cold. By using soap and water to wash your hands, you can prevent the spread of germs that can make you sick. When it comes to your own health, basic personal hygiene can also assist protect you from infecting others. A typical personal hygiene consists of following habits: Every day, washing your face and body Washing your hands after using the bathroom with soap Twice daily cleaning of the teeth When you sneeze or cough, using a tissue (or your sleeve) to cover your mouth and nose After touching pets and other animals, cleaning your hands Here's what you can do to reduce the spread of infection through a basic personal hygiene: Keeping Food In A Safe Environment Before and after cooking, wash your hands. Thus, you won't be able to contaminate food and won't get sick or spread bacteria from food, such as raw meat

Endocrinology is the study of hormones and glands in the human body. The endocrine system produces and secretes hormones that regulate many bodily functions, including growth and development, metabolism, and reproductive health. Endocrinologists are physicians who specialize in diagnosing and treating hormonal imbalances and disorders. There are several reasons why you might consider seeing an endocrinologist. In this article, we'll explore some of the most common reasons people seek out the expertise of an endocrinologist. YOU HAVE DIABETES If you have diabetes, it is important to consider seeing an endocrinologist. Endocrinologists specialize in managing diabetes and can help you develop a personalized treatment plan to manage your blood sugar levels. They can also help you prevent or manage complications of diabetes, such as nerve damage, kidney disease, and eye problems. An endocrinologist can work with you to develop a healthy lifestyle plan that includes diet, exercise, and medication management. They can also help you adjust your treatment plan as needed to ensure that your diabetes is well-controlled. Seeing an endocrinologist can help you achieve better health outcomes and improve your overall quality of life.

Discover top-rated gastroenterology services at Kailash Deepak Hospital East Delhi. Our expert gastroenterologists provide advanced care for digestive disorders, ensuring optimal health and well-being. Trust our renowned liver specialists in East Delhi for comprehensive treatment and compassionate care.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition. The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services. The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand. Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

Audio link How to Know Post Menopausal Osteoporosis disorder? What are its main signs and symptoms?

The Pharmacists' Defence Association (PDA) has reported growing concerns among its members regarding their safety at work as the far-right, anti-immigration riots escalate across the UK. "We have received calls from members who are concerned about their safety at work and feel vulnerable in communities where the violence and disorder are taking place," the organisation told Pharmacy Business. The PDA also reported that some hospital outpatient departments and GP surgeries were forced to close their doors to allow staff to get home safely, which may impact services to patients. In light of these challenges, the PDA is calling on employers to ensure that they are adequately communicating with pharmacists in locations at risk of conflict and to prioritise the health and safety of staff and patients. "We are aware that pharmacists and their teams working in areas where this criminal activity is taking place are feeling vulnerable but that they also want to ensure that their communities are safe and have access to the vital services pharmacies provide.

A snap survey conducted by the National Pharmacy Association (NPA) revealed that over half of community pharmacy teams have felt unsafe in the past week due to ongoing riots across the country. The survey, which included responses from approximately 350 community pharmacies, also found that one in three pharmacies had considered closing because of safety concerns, while 13 per cent of pharmacy teams reported experiencing racist comments during this period. According to the NPA, over 40 per cent of pharmacists are of South Asian, Black, or other ethnic minority backgrounds, with the majority of independent community pharmacy owners believed to be of South Asian heritage. The association reports that businesses had been vandalised during the riots, leading some pharmacies to reduce their opening hours or close entirely, following advice from the police and local authorities. Despite a recent decline in disorder over the last few days, police have been advised to remain on high alert over the weekend.

New Lamotrigine Desitin 10mg/ml Oral Suspension is the first licensed Lamotrigine oral liquid medicine available in the UK, offering simple, accurate and flexible dosing for vulnerable patient groups with epilepsy and bi-polar disorder. Accurate dosing and slow titration are essential when initially prescribing for patients with epilepsy. This helps minimise the risk of potentially life-threatening side effects such as Stevens-Johnson syndrome (an acute, rare, and occasionally fatal skin reaction). Dose escalation is required every 2 weeks until the optimal dose is achieved to reach the desired maintenance level. Lamotrigine Desitin 10mg/ml Oral Suspension helps simplify complex prescribing and dispensing regimes, as all dosing requirements are covered in a single product. The supplied dosing syringe and cup make it simple for patients to use and carers to administer. The licensed Oral Suspension is likely to be of benefit when prescribing for children (over 2 years), older people (particularly patients with dysphagia) and also those with learning disabilities. The 10mg/ml strength simplifies accurate dosing for children and offers complete flexibility when dosing is based on mg/kg body weight.

In response to significant ongoing disruptions in the supply of certain Quetiapine tablet strengths, the Department of Health and Social Care (DHSC) on Tuesday issued nine new Serious Shortage Protocols (SSPs), with immediate effect. These measures aim to ensure the continued availability of quetiapine, an essential medication for managing schizophrenia and bipolar disorder. Under the new SSPs, community pharmacists are allowed to consider different options to manage the shortage of the three strengths of quetiapine tablets affected by ongoing supply disruptions: quetiapine 300mg tablets, quetiapine 200mg tablets, and quetiapine 150mg tablets. Depending on the prescribed quantity of the affected quetiapine tablet, pharmacists can either supply a reduced quantity of the same quetiapine tablet or substitute with an alternative strength or provide a reduced quantity of a specific alternative product.

Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.